Literature DB >> 11243885

Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43.

A Westlind1, S Malmebo, I Johansson, C Otter, T B Andersson, M Ingelman-Sundberg, M Oscarson.   

Abstract

On the basis of the detection of an expressed sequence tag ('EST') similar to the human cytochrome P450 3A4 cDNA, we have identified a novel member of the human cytochrome P450 3A subfamily. The coding region is 1512-bp long and shares 84, 83, and 82% sequence identity on the cDNA level with CYP3A4, 3A5, and 3A7, respectively, with a corresponding amino acid identity of 76, 76, and 71%. Quantitative real time based mRNA analysis revealed CYP3A43 expression levels at about 0.1% of CYP3A4 and 2% of CYP3A5 in the liver, with significant expression in 70% of the livers examined. Gene specific PCR of cDNA from extrahepatic tissues showed, with the exception of the testis, only low levels of CYP3A43 expression. The CYP3A43 cDNA was heterologously expressed in yeast, COS-1 cells, mouse hepatic H2.35 cells and in human embryonic kidney (HEK) 293 cells, but in contrast to CYP3A4 which was formed in all cell types, no detectable CYP3A43 protein was produced. This indicates a nonfunctional protein or specific conditions required for proper folding. It is concluded that CYP3A43 mRNA is expressed mainly in liver and testis and that the protein would not contribute significantly to human drug metabolism. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11243885     DOI: 10.1006/bbrc.2001.4505

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  31 in total

Review 1.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

2.  CYP3A5 phenotype-genotype correlations in a British population.

Authors:  Barry P King; Julian B S Leathart; Elaine Mutch; Faith M Williams; Ann K Daly
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

Review 3.  Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

Authors:  Ron H N van Schaik
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

4.  Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein.

Authors:  A G Pinto; J Horlander; N Chalasani; M Hamman; A Asghar; D Kolwankar; S D Hall
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

5.  Decision tree-based modeling of androgen pathway genes and prostate cancer risk.

Authors:  Jill S Barnholtz-Sloan; Xiaowei Guan; Charnita Zeigler-Johnson; Neal J Meropol; Timothy R Rebbeck
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-04-14       Impact factor: 4.254

6.  Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers.

Authors:  Annika Allqvist; Jun Miura; Leif Bertilsson; Rajaa A Mirghani
Journal:  Eur J Clin Pharmacol       Date:  2007-01-03       Impact factor: 2.953

Review 7.  Significance of the minor cytochrome P450 3A isoforms.

Authors:  Ann K Daly
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

8.  The revised human liver cytochrome P450 "Pie": absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics.

Authors:  Scott Michaels; Michael Zhuo Wang
Journal:  Drug Metab Dispos       Date:  2014-05-09       Impact factor: 3.922

Review 9.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Effects of ursodeoxycholic acid on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam in healthy volunteers.

Authors:  Dongmei Yan; Yingbao Yang; Sinya Uchida; Shingen Misaka; Jinghui Luo; Kazuhiko Takeuchi; Naoki Inui; Shizuo Yamada; Kyoichi Ohashi; Hiroshi Watanabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-19       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.